Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release earnings results for the second quarter, after the closing <a href="https://www.benzinga.com/quote/KBH/earnings">bell on Monday, June 23</a>.
With the recent buzz around the Los Angeles-based firm, some investors may be eyeing potential gains from the company's dividends. Currently, KB Home offers an annual dividend yield of 1.93%. That&#8217;s a quarterly dividend amount of 25 cents per share ($1.00 a year).
To figure out how to earn $500 monthly from KB Home, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by KB Home's $1.00 dividend: $6,000 / $1.00 = 6,000 shares.
So, an investor would need to own approximately $310,500 worth of KB Home, or 6,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.00 = 1,200 shares, or $62,100 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
KBH Price Action: Shares of KB Home gained by 2.2% to close at $51.75 on Friday.
Analysts expect KB Home to report quarterly earnings at $1.46 per share, down from $2.15 per share in the year-ago. The company projects to report quarterly revenue at $1.51 billion, compared to $1.71 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, KB Home reported worse-than-expected first-quarter EPS and sales results.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a></li>
</ul>
Image: Shutterstock

Long Ideas

Dividends

How To Earn $500 A Month From KB Home Stock Ahead Of Q2 Earnings

Harmonic's cOS Platform Enables Mediacom to Offer Multigigabit and Symmetrical Services with High Reliability, Lower Operating Costs and a Clear Path to Fiber
SAN JOSE, Calif., June 23, 2025 /PRNewswire/ -- Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) today announced that Mediacom Communications, the fifth-largest cable operator in the U.S., has chosen Harmonic's industry-leading cOS&#x2122; virtualized broadband platform to modernize its network. The&nbsp;cOS platform allows Mediacom to offer multigigabit and symmetrical speeds and an enhanced subscriber experience with DOCSIS 4.0 broadband services as well as gain the optionality to add fiber services. This strategic deployment supports Mediacom's shift to a distributed access architecture (DAA) with Harmonic's Unified DOCSIS 4.0 solution, providing faster and lower-latency internet experiences for consumers.

HLIT

Mediacom Communications Selects Harmonic's cOS Virtualized Broadband Platform To Modernize Network

CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company"), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial's Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.
CERo CMO Robert Sikorski MD., PhD. noted, "The first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML patient. A second AML patient has been identified and has provided informed consent for participation in the trial."
CERo CEO Chris Ehrlich added, "Given that CER-1236 is a first-in-class biologic targeting a previously unexplored pathway, each milestone reached is significant. We remain focused on progressing methodically through each phase of this trial and are preparing to initiate our second trial of CER-1236 in solid tumors later this year. We continue to believe CER-1236 holds significant potential as a novel approach in cancer therapy and look forward to providing future updates."
CER-1236 is currently in Phase 1 clinical trials for AML. The first-in-human, multi-center, open label, Phase 1/1b study, titled, "Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell&nbsp;CER-1236&nbsp;in Patients With Acute Myeloid Leukemia (CertainT-1)," is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).

Biotech

General

CERo Therapeutics Holdings Announces First Patient Completes Dose-Limiting Toxicity Observation Period With No Reported DLTs In Phase 1 Trial Of CER-1236

KMTS

Kestra Medical Technologies To Be Added To Russell 3000 Index, With Automatic Inclusion In Russell 2000 Index, Effective June 27

<ul>
<li>Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 &nbsp;</li>
<li>Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review request &nbsp;</li>
<li>Company has received and complied with FDA information request for updated drug ingredient and label information on NRX-100 &nbsp;</li>
<li>Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine</li>
</ul>

NRXP

NRx Pharmaceuticals Announces Filing Of Commissioner's National Priority Voucher Application For Intravenous Ketamine

WIIM

Novo Nordisk shares are trading lower after the company announced it will no longer be working with Hims & Hers Health and it will not provide it direct access to Wegovy via NovoCae Pharmacy.

JP Morgan analyst Daniel Politzer initiates coverage on PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Overweight rating and announces Price Target of $24.

Price Target

Initiation

Analyst Ratings

PENN

JP Morgan Initiates Coverage On PENN Entertainment with Overweight Rating, Announces Price Target of $24

Term loan maturity extended by 12 months to June 2029
Principal balance on term loan expanded to $13.0 million from $11.1 million currently
Expanded revolving line of credit facility by $1.5 million
Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025
DENVER, CO / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 23, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced it has successfully expanded and extended its lending agreement with Eclipse Business Capital LLC ("Eclipse"), providing added working capital flexibility as the Company prepares for the commercial launch of EXXUA&#x2122; (gepirone) extended-release tablets ("EXXUA"). Gepirone is a new chemical entity, and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration ("FDA") for the treatment of major depressive disorder ("MDD") in adults.
Earlier this month, Aytu announced an exclusive agreement to commercialize EXXUA in the United States entering the Company into the over $22 billion United States prescription MDD market. Over 340 million antidepressant prescriptions were written in 2024 in the United States, yet significant unmet needs remain considering the unacceptable side effects associated with current therapeutics. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.

AYTU

Aytu BioPharma Expands And Extends Lending Agreement With Eclipse Business Capital, Providing Added Working Capital Flexibility As Aytu Prepares For Commercial Launch Of EXXUA Extended-Release Tablets

B of A Securities analyst Heather Balsky downgrades Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) from Buy to Neutral and lowers the price target from $300 to $285.

Downgrades

B of A Securities Downgrades Equifax to Neutral, Lowers Price Target to $285

JP Morgan analyst Daniel Politzer initiates coverage on MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Neutral rating and announces Price Target of $38.

JP Morgan Initiates Coverage On MGM Resorts International with Neutral Rating, Announces Price Target of $38

<a href="https://www.globenewswire.com/Tracker?data=XirGA5aw79jfnb954sJ8SO-QlmTWEPUdfHRnU_c8XfLyv01hCB7R-79L-P0cPcb74skAsYHKmOo7MY6GZHTfwxcPr0jZKblewWWMGUcTL70=">SharpLink Gaming, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) ("SharpLink" or the "Company"), the largest publicly traded holder of ETH in the world, today announced that the Company's common stock has been approved for options trading on the Nasdaq Options Market ("Nasdaq").
Options trading on SharpLink will be available through the Options Clearing Corporation ("OCC"), and will be subject to standard rules and regulations established by Nasdaq and the OCC.

SBET

SharpLink Gaming Common Stock Approved For Options Trading On Nasdaq Options Market

Goldman Sachs analyst Leah Jordan initiates coverage on Pilgrims Pride (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) with a Neutral rating and announces Price Target of $50.

Goldman Sachs Initiates Coverage On Pilgrims Pride with Neutral Rating, Announces Price Target of $50

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg.jpeg" alt="" class="wp-image-14738" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The satellite positioning chip designer previously planned to float shares on China's domestic A-share market, but has shifted its sights to Hong Kong with its new listing application 
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Hong Kong IPO applicant Allystar Technology continues to report losses, but could soon become profitable as it achieves economies of scale and other greater efficiencies</li>
<li>The company has signed strategic partnerships with many big tech names such as Meituan, BYD and ZTE</li>
</ul>
The rise of location-based apps and smart cities, combined with a new dawn of the internet of everything (IoE), has created strong demand for positioning services that are putting&nbsp;Allystar Technology (Shenzhen) Co. Ltd.&nbsp;on the investor map. Now, the leading positioning chip designer is trying to cash in on its rising star with a recent application to list in Hong Kong.
The company has done some directional shifting of its own, moving its sights to the more internationally focused Hong Kong after originally planning to chase a listing on China's domestic A-share market.
Allystar uses navigation chip technology and an R&amp;D team it acquired in 2017 from&nbsp;Huada Technology&nbsp;(0085.HK), a subsidiary of state-run electronics giant China Electronics Corp. (CEC), a year after its founding by seven shareholders, according to its listing document filed earlier this month. It began mass producing its dual-frequency high-precision navigation and positioning system-on-chips (SoC) in 2019 for use in the BeiDou system, China's homegrown alternative to the globally popular U.S.-based GPS. Since then, it has also begun making chips for use in other major global positioning systems, including GPS.
Allystar's current shareholding is quite diverse, with no single company holding more than 10% of its stock. Its largest shareholder is CEC subsidiary China Electronics Optics Valley Union (0798.HK), which holds a 9.2%. Other shareholders include China Citic Bank and China Merchants Bank, with 7.2% and 7.1% stakes, respectively. New energy vehicle and battery giant BYD (1211.HK; 002594.SZ) is also an early investor with 4.1%, while fellow carmaker SAIC Motor holds 1.8% through a joint venture. Robert Bosch Venture Capital, an investment arm of German automotive parts giant Bosch, also holds 2.95%.
<h4 class="wp-block-heading">Sixth-largest global positioning chip supplier</h4>
Global navigation satellite systems provide positioning, navigation, and timing services via satellites and chips, and are used to help apps determine global positioning. Four such systems are currently operating worldwide, including China's BeiDou, the U.S. GPS, Russia's Glonass and the EU's Galileo.
Allystar's SoC products are ultra-low in power consumption and use AI-integrated positioning algorithms. The company uses an asset-light model of designing its chips and manufacturing them using third-party foundries. It is the sixth-largest such chipmaker globally with 4.8% of the market, and the second largest in China, based on its units shipped.
The global positioning services market is growing rapidly, worth about 2 trillion yuan ($278 billion) in 2023 alone, driven by development of mobile internet and internet of things (IoT) technologies. Rapid AI advancements fueling a new wave of increasingly sophisticated consumer electronics, along with rapid growth in automotive intelligence and the low-altitude economy, are expected to keep the market growing by 9.1% annually to reach 3.25 trillion yuan by 2028, according to third-party market data in Allystar's listing document.
<h4 class="wp-block-heading">Sales, R&amp;D spending drag</h4>
Allystar's revenue comes from two main segments: global navigation chips, modules, and related solutions; and high-precision chips and modules. Last year, those two accounted for 28.3% and 71.7% of its revenue. Global navigation chips contributed 238 million yuan and high precision chips provided 602 million yuan, bringing the total to 840 million yuan, up 30.2% year-on-year.
It's worth noting that while the high-precision chip and module business is the company's biggest breadwinner, that segment's gross margin was extremely low at just 2.8% last year. By comparison, the smaller global navigation segment had lower revenue but a much higher gross margin of 27.3%. As a result, global navigation chips contributed 65 million yuan of Allystar's gross profit last year, much higher than the 17 million yuan provided by the high-precision chips and modules business. The company's total gross profit of 82 million yuan last year was also up by 20.7% from 2023.
Despite the strong revenue and gross profit growth, the company still reported a loss of 141 million yuan last year due to significant sales and R&amp;D costs. That said, the loss still narrowed by roughly half from 2023.
Allystar believes it can continue to stem the flow of red ink and become profitable, stating it plans to reach such a goal in the near future by improving its gross margin, enhancing its operational efficiency and optimizing its working capital management. The company points out it expects its gross margin to significantly improve as companies roll out increasingly sophisticated global positioning products and solutions, and that such growing demand will also help it to reach greater economies of scale.
<h4 class="wp-block-heading">Fragmented shareholding</h4>
Allystar's client portfolio looks quite strong, featuring strategic tie-ups with the likes of takeout dining giant Meituan, bike-sharing operators Hello Inc. and DiDi Bike, smart vehicle technology companies BYD, ZTE and SAIC Motor, and telecoms carriers China Mobile and China Unicom in the smart cities space.
Hong Kong-listed chip designers are doing well in general lately, which could help to boost sentiment towards Allystar's offering. Among those,&nbsp;Horizon Robotics&nbsp;(9660.HK) and&nbsp;Black Sesame&nbsp;(2533.HK) current trade at healthy price-to-sales (P/S) ratios of 12 times and 9 times, respectively. Allystar's 840 million yuan in revenue last year and a similar P/S ratios of 7 times to 8 times would value the company at about 6.3 billion yuan, near unicorn status defined as a market value of more than $1 billion.
But one key concern could be Allystar's highly fragmented shareholding structure. Its largest stakeholder owns less than 10% of its shares, while as many as 42 hold less than 3%, and 21 hold less than 1%. Many of those smaller holders are quite likely to sell their stakes after the company's lock-up period expires, which could create some volatility for the stock as the company tries to position in the global investor constellation.

Asia

IPOs

Opinion

Fragmented Shareholding Positions Allystar For Turbulence

B of A Securities analyst Adrien de Saint Hilaire upgrades Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) from Underperform to Neutral and maintains the price target from $80 to $80.

Upgrades

B of A Securities Upgrades Omnicom Group to Neutral, Maintains Price Target to $80

A <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4453724-1&amp;h=1831616177&amp;u=https%3A%2F%2Fwww.leidos.com%2F&amp;a=Leidos">Leidos</a>-led (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) modernization initiative, involving companies from France, Germany, Italy, and the U.K., aims to enhance NATO's IT infrastructure. The project is designed to improve resilience against cyber threats and increase efficiency and scalability, in support of NATO digital transformation.
Leidos was awarded a contract from the NATO Communications and Information Agency (NCIA) for the provision of a centralized IT solution (based on private cloud technology) to support NATO's operational network, integrating core services such as service management and cybersecurity with the goal of enhancing interoperability and operational efficiency across the NATO command structure.
"This project reflects our long-standing commitment to NATO, leveraging innovative solutions aimed at delivering secure, mission-ready capabilities designed to adapt with operational needs," said Steve Hull,&nbsp;Leidos&nbsp;digital modernization sector president. "It also creates new opportunities for more integrated collaboration across trans-Atlantic defense networks, helping NATO teams stay securely connected and able to share critical information with greater speed, agility and assurance."
Thales (France), CGI (Germany), Leonardo (Italy), LA International (U.K.) and NEXOR (U.K.) are joining Leidos as a multi-national team with extensive knowledge of NATO requirements and a strong track record of delivering results. Collectively, they have supported NATO's work for decades.
The IT Modernization Recovery Increment 1 Systems Integration contract bolsters Leidos' role as a key technology partner with NCIA, supporting NATO's mission and advancing secure cloud modernization. It has a ceiling value of $87 million (€79.1 million) on indefinite delivery indefinite quantity (IDIQ) firm-fixed price terms. &nbsp;

Contracts

LDOS

Leidos Announces It Was Awarded A Contract From The NATO Communications And Information Agency

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares moved upwards by 16.7% to $0.11 during Monday's pre-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 13.92% to $1.04. The market value of their outstanding shares is at $17.5 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares rose 8.6% to $2.02. The company's market cap stands at $4.4 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock moved upwards by 7.26% to $0.74. The company's market cap stands at $6.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) shares fell 13.8% to $1.81 during Monday's pre-market session. The company's market cap stands at $94.0 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock fell 12.56% to $6.55. The market value of their outstanding shares is at $4.1 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) stock fell 9.43% to $1.63. The market value of their outstanding shares is at $32.0 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock fell 6.69% to $0.51. The company's market cap stands at $39.0 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined by 6.27% to $0.46. The company's market cap stands at $9.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock declined by 6.1% to $9.25. The market value of their outstanding shares is at $601.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

FTEL

JFBR

KBSX

NTCL

TRNR

XELB

10 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock increased by 141.3% to $0.65 during Monday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 104.55% to $0.74. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares moved upwards by 66.84% to $35.07. The company's market cap stands at $272.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock moved upwards by 40.78% to $20.64. The company's market cap stands at $96.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares moved upwards by 33.18% to $0.59. The market value of their outstanding shares is at $18.4 million. </li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock increased by 23.13% to $49.71. The market value of their outstanding shares is at $11.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares declined by 35.2% to $3.0 during Monday's pre-market session. The company's market cap stands at $433.1 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares declined by 21.39% to $5.44. The company's market cap stands at $1.3 billion. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares decreased by 18.19% to $3.51. The market value of their outstanding shares is at $7.0 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 17.13% to $53.22. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.13% to $0.27. The company's market cap stands at $3.8 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 13.32% to $3.06. The market value of their outstanding shares is at $10.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARM

CDTX

CMPS

EXEL

FBRX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LUCY

PCSA

SSII

TCRT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock rose 56.9% to $2.26 during Monday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares moved upwards by 28.41% to $7.86. The company's market cap stands at $14.6 million. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares moved upwards by 22.18% to $1.2. The company's market cap stands at $33.1 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) stock rose 14.47% to $0.72. The market value of their outstanding shares is at $5.6 million. </li>
<li>Energy Focus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) shares moved upwards by 13.85% to $1.89. The company's market cap stands at $8.9 million. </li>
<li>SU Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares rose 13.57% to $0.52. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares declined by 21.4% to $0.2 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares fell 15.14% to $0.34. The company's market cap stands at $11.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock fell 12.27% to $3.29. The company's market cap stands at $10.1 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) stock fell 12.0% to $4.4. The market value of their outstanding shares is at $53.0 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) stock decreased by 10.72% to $2.0. The company's market cap stands at $100.8 million. </li>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares declined by 10.71% to $0.75. The market value of their outstanding shares is at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

CDTG

DFLI

EFOI

HCAI

NEPH

RAYA

RBNE

RYDE

SUGP

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) shares rose 19.2% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $119.5 million. </li>
<li>Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) stock rose 17.63% to $16.68. The market value of their outstanding shares is at $3.3 billion. </li>
<li>SemiLEDs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) stock moved upwards by 16.73% to $3.0. The market value of their outstanding shares is at $18.5 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) stock rose 12.58% to $0.68. The company's market cap stands at $39.8 million. </li>
<li>Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) shares increased by 8.39% to $5.68. The company's market cap stands at $166.8 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock rose 7.58% to $1.13. The company's market cap stands at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock decreased by 29.9% to $2.41 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares decreased by 15.27% to $1.11. The market value of their outstanding shares is at $4.1 million. </li>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) stock fell 13.35% to $0.78. The market value of their outstanding shares is at $140.0 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock decreased by 11.03% to $1.13. The market value of their outstanding shares is at $13.0 million. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock declined by 8.12% to $4.3. The market value of their outstanding shares is at $2.9 million. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) shares decreased by 5.91% to $2.55. The market value of their outstanding shares is at $275.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AISP

AUUD

BZAI

DVLT

LEDS

MRIN

Next Technology Holding Inc. - Ordinary Shares

NXTT

SONM

SQNS

WOLF

ZETA

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the&nbsp;United States Department of Health and Human Services&nbsp;(HHS) for BAT&#xAE; [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT&#xAE;, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.

Emergent Biosolutions Bags $62.4M Contract Modification From United States Department Of HHS' ASPR For BAT

Financing

Press Releases

NewGen Secures Strategic Funding to Drive International Expansion and Corporate Growth

NewGen Filed 2024 Annual Report on Form 20-F

Health Care

NewGenIVF Announces Reverse Stock Split

NewGenIVF Introduces NewGenSort to Support Men's Reproductive Health Across Asia

NewGen Announces Strategic Expansion with Services Tailored for Indian Medical Tourists

NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!

NewGen Announces Planned US$45 Million Strategic Investment in UAE Real Estate Market

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

AEMD

ASPI

BIXT

CSE:PMC

CSE:SUR

CYIO

EYEN

JAGX

KPRX

LGCXF

OMEX

PMCCF

PNPNF

PRSO

RGBP

SEVCF

SNYR

SRGZ

SURMF

TRAW

TSX:URE

TSX:VGZ

TSXV:LG

TSXV:PNPN

TZUP

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Precipio

Quipt Home Medical

Vivos Therapeutics

Screenshot 2025-03-05 at 6.43.43 PM

NewGenIvf Taps Veteran Healthcare Executive To Build Out Its New Egg Freezing Service

Screenshot 2025-02-24 at 6.31.24 PM

NewGenIvf Inks $5 Million Deal To Buy Sperm-Sorting Technology Company MicroSort, Eyes China Expansion

The Search Is Over: NewGenIVF Inks Reverse Merger Agreement With European Wellness Investment Holdings

Comments

NewGenIvf Group

Noticias

Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL